Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
Economy

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)

Last updated: July 12, 2025 12:35 am
Share
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR)
SHARE

United Therapeutics Corp. (NASDAQ:UTHR) has been identified as one of the top debt-free stocks to invest in right now. The company’s strong portfolio is anchored by Tyvaso, an inhaled therapy for pulmonary hypertension, along with a robust pipeline focused on pulmonary arterial hypertension (PAH). With a 17% year-over-year growth in Q1 2025 revenue and a 17% compounded annual growth rate (CAGR) over the last five years, United Therapeutics is demonstrating impressive topline and earnings growth.

UBS analyst Ashwani Verma recently reiterated a Buy rating on United Therapeutics (NASDAQ:UTHR) but adjusted the price target to $385 from $410. This adjustment reflects a recalibration of expectations ahead of a key clinical update, specifically the upcoming Phase III readout for idiopathic pulmonary fibrosis (IPF) expected in the third quarter. Verma sees this as a high-impact event that could significantly influence the stock, and believes the risk/reward ratio remains favorable at current valuation levels.

Verma also pointed out Tyvaso as a bright spot for United Therapeutics, anticipating strong performance in both Q2 and Q3 which should bolster near-term revenue growth. While United Therapeutics presents a compelling investment opportunity, there are other AI stocks that may offer greater upside potential with lower downside risk. For investors seeking an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, exploring the best short-term AI stock could be worthwhile.

In conclusion, United Therapeutics Corp. continues to show strong growth potential with its innovative therapies and promising pipeline. As investors evaluate their options in the healthcare and biotechnology sectors, United Therapeutics remains a company to watch. For more investment insights and stock picks, readers can explore reports on other top stock picks and undervalued momentum stocks. Please note that the information provided in this article is for informational purposes only and does not constitute investment advice.

See also  Microsoft Tops Q2 Estimates and Unveils Landmark UK AI Investment
TAGGED:BullishPriceStaysTargetTherapeuticstrimsUBSUnitedUTHR
Share This Article
Twitter Email Copy Link Print
Previous Article Planet Discovery Reveals Out-of-Sync Double Star System : ScienceAlert Planet Discovery Reveals Out-of-Sync Double Star System : ScienceAlert
Next Article Bella Thorne Accuses Charlie Puth of ‘Hate Train’ Over Refusal Bella Thorne Accuses Charlie Puth of ‘Hate Train’ Over Refusal
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Louis Vuitton Spring 2026 Menswear Collection

Louis Vuitton's menswear show was a sight to behold, with a stunning set inspired by…

June 24, 2025

Stephen A. Smith Reacts To Shannon Sharpe Leaving ESPN Amid Rape Lawsuit

Stephen A. Smith Reacts To Shannon Leaving ESPN Amid Rape Lawsuit Published on April 25,…

April 25, 2025

GOP Senator Breaks Ranks With Trump On Key Issue

Sen. John Curtis (R-Utah) did not join the few Republican lawmakers who criticized President Donald…

May 20, 2025

5 Best Tweezers, According to Brow Experts

When it comes to grooming your eyebrows, having the right tools can make all the…

August 12, 2025

MSNBC President Rebecca Kutler Reveals Cancer Diagnosis

Rebecca Kutler, who serves as the president of MSNBC, has received a breast cancer diagnosis.…

October 15, 2025

You Might Also Like

Dan Ives’ AI ETF Hits B in Assets Just Five Months After Launch
Economy

Dan Ives’ AI ETF Hits $1B in Assets Just Five Months After Launch

October 31, 2025
Is This The Best ETF to Invest In Ahead of Potential AI Bubble Burst?
Economy

Is This The Best ETF to Invest In Ahead of Potential AI Bubble Burst?

October 31, 2025
Alphabet hikes capex again after earnings beat on strong ad, cloud demand
Economy

Alphabet hikes capex again after earnings beat on strong ad, cloud demand

October 31, 2025
What is a merchant bank?
Economy

What is a merchant bank?

October 30, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?